参考文献/References:
[1] APPELMAN-DIJKSTRA N M,OEI H,VLUG A G,et al.The effect of osteoporosis treatment on bone mass[J].Best Pract Res Clin Endocrinol Metab,2022,36(2):101623.
[2] SALARI N,GHASEMI H,MOHAMMADI L,et al.The glo-bal prevalence of osteoporosis in the world:a comprehensive systematic review and meta-analysis[J].J Orthop Surg Res,2021,16(1):609.
[3] WANG M,SEIBEL M J.Approach to the patient with bone fracture:making the first fracture the last[J].J Clin Endocrinol Metab,2023,108(12):3345-3352.
[4] YAN C,SHI Y,YUAN L,et al.Mitochondrial quality control and its role in osteoporosis[J].Front Endocrinol(Lausanne),2023,14:1077058.
[5] RAKHA A,UMAR N,RABAIL R,et al.Anti-inflammatory and anti-allergic potential of dietary flavonoids:a review[J].Biomed Pharmacother,2022,156:113945.
[6] 龚凌霄,迟海林,曹文燕,等.黄酮类物质预防骨质疏松症的研究进展[J].现代食品科技,2017,33(7):328-335.
[7] 赵继荣,杨文通,胡继宏,等.天然化合物黄酮抗炎作用信号通路机制研究进展[J].中华中医药学刊,2023,41(7):10-14.
[8] WANG X,MA Y,XU Q,et al.Flavonoids and saponins:what have we got or missed?[J].Phytomedicine,2023,109:154580.
[9] 周梓洋,赵艺欣,于静波,等.甘草活性成分及抗抑郁机制的研究进展[J].中草药,2025,56(11):4136-4146.
[10] 何仪恬,方士元,路璐,等.淫羊藿提取过程中黄酮醇苷成分变化规律研究[J].中药材,2025(10):2576-2582.
[11] 安国尧,元宝华,贾潇,等.葛根素防治骨质疏松症的分子机制研究进展[J].中国骨质疏松杂志,2025,31(12):1859-1865.
[12] 张卫花,韩可祯,赵可心,等.基于多组学技术探讨中药黄酮类化合物在疾病治疗中的应用[J].中南大学学报(医学版),2025,50(10):1915-1929.
[13] 韩旭,李英华,洪洋.富含黄酮类化合物的中药材在骨质疏松治疗中的研究进展[J].中医临床研究,2025,17(18):107-114.
[14] ZHAO T,ZHANG J,LEI H,et al.NRF1-mediated mitochondrial biogenesis antagonizes innate antiviral immunity[J].EMBO J,2023,42(16):e113258.
[15] SPRENGER H G,LANGER T.The good and the bad of mitochondrial breakups[J].Trends Cell Biol,2019,29(11):888-900.
[16] THAYER J A,PETERSEN J D,HUANG X,et al.A unified mechanism for mitochondrial damage sensing in PINK1-Parkin-mediated mitophagy[J].EMBO J,2025,45(1):64-105.
[17] CHOI E H,KIM M H,PARK S J.Targeting mitochondrial dysfunction and reactive oxygen species for neurodegenerative disease treatment[J].Int J Mol Sci,2024,25(14):7952.
[18] JAGTAP Y A,CHOUDHARY A,KINGER S,et al.Mitochondrial proteostasis and cellular health:insights from chaperones and autophagy[J/OL].J Physiol,2025[2026-01-19]. https://pubmed.ncbi.nlm.nih.gov/40048126/.
[19] 齐朋朋,李志超,徐展望,等.骨质疏松症中的线粒体质量控制[J].中国骨质疏松杂志,2024,30(4):582-587.
[20] COPPI L,LIGORIO S,MITRO N,et al.PGC1s and beyond:disentangling the complex regulation of mitochondrial and cellular metabolism[J].Int J Mol Sci,2021,22(13):6913.
[21] POPOV L D.Mitochondrial biogenesis:an update[J].J Cell Mol Med,2020,24(9):4892-4899.
[22] ABU SHELBAYEH O,ARROUM T,MORRIS S,et al.PGC-1α is a master regulator of mitochondrial lifecycle and ROS stress response[J].Antioxidants(Basel),2023,12(5):1075.
[23] YU B,HUO L,LIU Y,et al.PGC-1α controls skeletal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing TAZ[J].Cell Stem Cell,2018,23(2):193-209.
[24] BAI Y,WU Z,LEARY S C,et al.Focal adhesion kinase alleviates simulated microgravity-induced inhibition of osteoblast differentiation by activating transcriptional Wnt/β-Catenin-BMP2-COL1 and metabolic SIRT1-PGC-1α-CPT1A pathways[J].Int J Mol Sci,2025,26(4):1669.
[25] DING Y,YANG H,WANG Y,et al.Sirtuin 3 is required for osteogenic differentiation through maintenance of PGC-1ɑ-SOD2-mediated regulation of mitochondrial function[J].Int J Biol Sci,2017,13(2):254-264.
[26] TINKOV A A,KIM H,SKALNY A V,et al.The role of mitochondrial quality control in manganese-induced neuro-toxicity[J].Neurotox Res,2025,44(1):2.
[27] SHIRES S E,QUILES J M,NAJOR R H,et al.Nuclear parkin activates the ERRα transcriptional program and drives widespread changes in gene expression following hypoxia[J].Sci Rep,2020,10(1):8499.
[28] TSUNEMI T,ASHE T D,MORRISON B E,et al.PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function[J].Sci Transl Med,2012,4(142):142ra97.
[29] TÁBARA L C,SEGAWA M,PRUDENT J.Molecular mechanisms of mitochondrial dynamics[J].Nat Rev Mol Cell Biol,2025,26(2):123-146.
[30] SABOUNY R,SHUTT T E.Reciprocal regulation of mitochondrial fission and fusion[J].Trends Biochem Sci,2020,45(7):564-577.
[31] SHI Q,SONG Y,CAO J,et al.Inhibition of mitochondrial fission reverses simulated microgravity-induced osteoblast dysfunction by enhancing mechanotransduction and epigenetic modification[J].Research(Wash D C),2025,8:0602.
[32] GAN X,HUANG S,YU Q,et al.Blockade of Drp1 rescues oxidative stress-induced osteoblast dysfunction[J].Biochem Biophys Res Commun,2015,468(4):719-725.
[33] JEONG S,SEONG J H,KANG J H,et al.Dynamin-related protein 1 positively regulates osteoclast differentiation and bone loss[J].FEBS Lett,2021,595(1):58-67.
[34] ZHAO J,WANG Q,CAO Y,et al.Mapping the global research landscape of mitophagy in Parkinson's disease:a bibliometric and visualization analysis[J].Hereditas,2025,162(1):230.
[35] CHANG X,LOCHNER A,WANG H H,et al.Coronary microvascular injury in myocardial infarction:perception and knowledge for mitochondrial quality control[J].Theranostics,2021,11(14):6766-6785.
[36] ZHANG X,XIE F,MA S,et al.Mitochondria:one of the vital hubs for molecular hydrogen's biological functions[J].Front Cell Dev Biol,2023,11:1283820.
[37] D'ARCY M S.Mitophagy in health and disease.Molecular mechanisms,regulatory pathways,and therapeutic implications[J].Apoptosis,2024,29(9/10):1415-1428.
[38] BAKULA D,SCHEIBYE-KNUDSEN M.Mitophaging:mitophagy in aging and disease[J].Front Cell Dev Biol,2020,8:239.
[39] ONISHI M,YAMANO K,SATO M,et al.Molecular mechanisms and physiological functions of mitophagy[J].EMBO J,2021,40(3):e104705.
[40] BADER V,WINKLHOFER K F.PINK1 and Parkin: team players in stress-induced mitophagy[J].Biol Chem,2020,401(6/7):891-899.
[41] ZENG Z,ZHOU X,WANG Y,et al.Mitophagy—a new target of bone disease[J].Biomolecules,2022,12(10):1420.
[42] LEE S Y,AN H J,KIM J M,et al.PINK1 deficiency impairs osteoblast differentiation through aberrant mitochondrial homeostasis[J].Stem Cell Res Ther,2021,12(1):589.
[43] FAN S,LI J,ZHENG G,et al.WAC facilitates mitophagy-mediated MSC osteogenesis and new bone formation via protecting PINK1 from ubiquitination-dependent degradation[J].Adv Sci(Weinh),2025,12(2):e2404107.
[44] LIU F,YUAN Y,BAI L,et al.LRRc17 controls BMSC senescence via mitophagy and inhibits the therapeutic effect of BMSCs on ovariectomy-induced bone loss[J].Redox Biol,2021,43:101963.
[45] KOWALCZYK P,SULEJCZAK D,KLECZKOWSKA P,et al.Mitochondrial oxidative stress—a causative factor and therapeutic target in many diseases[J].Int J Mol Sci,2021,22(24):13384.
[46] WANG Y,BRANICKY R,NOE A,et al.Superoxide dismutases:dual roles in controlling ROS damage and regulating ROS signaling[J].J Cell Biol,2018,217(6):1915-1928.
[47] TAO H,GE G,LIANG X,et al.ROS signaling cascades:dual regulations for osteoclast and osteoblast[J].Acta Biochim Biophys Sin(Shanghai),2020,52(10):1055-1062.
[48] DENG S,DAI G,CHEN S,et al.Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3β signaling pathway[J].Biomed Pharmacother,2019,110:602-608.
[49] ZHANG S,LIU Y,LIANG Q.Low-dose dexamethasone affects osteoblast viability by inducing autophagy via intracellular ROS[J].Mol Med Rep,2018,17(3):4307-4316.
[50] YANG Y,LIU Z,WU J,et al.Nrf2 mitigates RANKL and M-CSF induced osteoclast differentiation via ROS-dependent mechanisms[J].Antioxidants(Basel),2023,12(12):2094.
[51] LI D,WU Q,LI Z,et al.Exploring the therapeutic mechanism of xinbao pill in brain injury after cardiopulmonary resuscitation based on network pharmacology,metabolomics,and experimental verification[J].CNS Neurosci Ther,2025,31(3):e70297.
[52] CHEN H,FAN W,HE H,et al.PGC-1:a key regulator in bone homeostasis[J].J Bone Miner Metab,2022,40(1):1-8.
[53] JUNG H Y,LEE D,RYU H G,et al.Myricetin improves endurance capacity and mitochondrial density by activating SIRT1 and PGC-1α[J].Sci Rep,2017,7(1):6237.
[54] SUH K S,RHEE S Y,KIM Y S,et al.Protective effect of liquiritigenin against methylglyoxal cytotoxicity in osteoblastic MC3T3-E1 cells[J].Food Funct,2014,5(7):1432-1440.
[55] LI M,YU Y,XUE K,et al.Genistein mitigates senescence of bone marrow mesenchymal stem cells via ERRα-mediated mitochondrial biogenesis and mitophagy in ovariectomized rats[J].Redox Biol,2023,61:102649.
[56] SHIN J W,WU Y,KANG Y G,et al.The effects of epigallocatechin-3-gallate and mechanical stimulation on osteogenic differentiation of human mesenchymal stem cells:individual or synergistic effects[J].Tissue Eng Regen Med,2017,14(3):307-315.
[57] ZHOU S,HUANG J,CHEN K,et al.Attenuating bone loss in osteoporosis:the potential of corylin(CL)as a therapeutic agent[J].Aging(Albany NY),2024,16(11):9569-9583.
[58] SARKAR J,DAS M,HOWLADER M S I,et al.Epigalloca-techin-3-gallate inhibits osteoclastic differentiation by modulating mitophagy and mitochondrial functions[J].Cell Death Dis,2022,13(10):908.
[59] WANG L,QU Y,HU Z,et al.Kaempferol ameliorates BMSCs senescence in postmenopausal osteoporosis by targeting Sp1 to activate FUNDC1-mediated mitophagy[J].Phytomedicine,2025,148:157456.
[60] WANG N,WANG L,YANG J,et al.Quercetin promotes osteogenic differentiation and antioxidant responses of mouse bone mesenchymal stem cells through activation of the AMPK/SIRT1 signaling pathway[J].Phytother Res,2021,35(5):2639-2650.
[61] JING X,DU T,CHEN K,et al.Icariin protects against iron overload-induced bone loss via suppressing oxidative stress[J].J Cell Physiol,2019,234(7):10123-10137.
[62] XIAN Y,SU Y,LIANG J,et al.Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation[J].Biochem Pharmacol,2021,193:114761.
[63] CAO S,WANG Y,ZHANG Y,et al.Naringenin can inhibit the pyroptosis of osteoblasts by activating the Nrf2/HO-1 signaling pathway and alleviate the differentiation disorder of osteoblasts caused by microgravity[J].J Agric Food Chem,2024,72(46):25586-25600.
[64] CHAI S,YANG Y,WEI L,et al.Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling[J].Phytomedicine,2024,128:155516.
[65] LI H,DENG W,YANG J,et al.Corylifol a suppresses osteo-clastogenesis and alleviates ovariectomy-induced bone loss via attenuating ROS production and impairing mitochondrial function[J].Biomed Pharmacother,2024,171:116166.
相似文献/References:
[1]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的
胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[2]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):7.
[3]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):12.
[4]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统
在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[5]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(06):27.
[6]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证
患者骨密度的影响[J].中医正骨,2013,25(11):19.
Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(06):19.
[7]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(06):20.
[8]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(06):5.
[9]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(06):21.
[10]陈俊杰,李晴晴,夏瑢.脂代谢及血清内脂素水平与绝经后骨质疏松症的
相关性研究[J].中医正骨,2012,24(04):16.
CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(06):16.
[11]曾韵杰,李小韵,陈桐莹,等.老年性骨质疏松症与线粒体功能障碍的关系及中医药治疗策略[J].中医正骨,2026,38(01):63.